LD-2 disclosure · 1st Quarter - Report
NATIONAL KIDNEY FOUNDATION
Client
- Location
- New York · United States of America
Registrant
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesBudget/Appropriations
FY 2026 and FY 2027 Appropriations for organ donation and transplantation activities (HRSA). FY 2026 and FY 2027 Appropriations for CDC, including the Chronic Kidney Disease Initiative. FY 2026 and FY 2027 Appropriations for kidney research at the National Institute of Diabetes and Digestive and Kidney Diseases. FY 2026 and FY 2027 Appropriations for Dept. of Defense Congressionally Directed Medical Research Program. FY 2026 and FY 2027 Appropriations for Indian Health Service.
LobbyistsTROY ZIMMERMAN · LAUREN DREW
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Centers For Disease Control & Prevention (CDC) · Health Resources & Services Administration (HRSA) · Indian Health Service · Natl Institutes of Health (NIH)
Health Issues
Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582). Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Support for xenotransplantation. Comment letter in support for FDA approval of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Activities in support of access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.
LobbyistsTROY ZIMMERMAN · LAUREN DREW · ms MIRIAM ELIZABETH GODWIN
